Why does tamoxifen increase the risk of endometrial cancer?

In endometrial tissue, tamoxifen exhibits properties of a partial estrogen receptor agonist, which stimulates proliferative processes in the uterus with prolonged use.

What is the advantage of raloxifene over tamoxifen?

Raloxifene is an antagonist in both breast and endometrial tissues, so it does not increase the risk of uterine hyperplasia and cancer.

What happens to estrogen receptors under the action of tamoxifen?

An unproductive receptor-drug complex is formed, followed by the depletion of the receptor pool (down-regulation).

Home › Pharmacology › Tamoxifen

Tamoxifen

Tamoxifenum

For medical students2 min readUpdated 2026-10-10

Tamoxifen is an antineoplastic agent belonging to the class of selective estrogen receptor modulators (SERMs). It is used in the treatment of hormone-dependent tumors by blocking the action of estrogens in breast tissue.

Pharmacological groupAntineoplastic agent, selective estrogen receptor modulator (SERM).

Dosage formsTablets: 10 mg, 20 mg, 30 mg, and 40 mg.

Mechanism of actionCompetitive blockade of estrogen receptors, inhibition of hormone-dependent cell growth.

Route of administrationOral, daily dose 20–40 mg.

Mechanism of Action

Tamoxifen is a triphenylethylene derivative. Its action is based on competition with estradiol for binding to $\alpha$- and $\beta$-estrogen receptors. Upon binding to the receptor, the drug induces specific conformational changes that determine its tissue specificity. Depending on the tissue type and the set of coreactivators or corepressors, tamoxifen can exhibit both antagonist and agonist properties.

Pharmacological Effects

The drug's effects depend on receptor localization:

Breast tissue: Acts as an antagonist, blocking cell proliferation.
Bone tissue: Exhibits agonist properties, helping to prevent osteoporosis.
Endometrium: Acts as a partial agonist, creating a risk of hyperplasia with prolonged use.

Indications

The primary indication is breast cancer in postmenopausal women. The drug inhibits hormone-dependent growth of tumor cells, an effect that is independent of the cell cycle phase.

Adverse Effects and Risks

Tamoxifen therapy is associated with several adverse reactions:

Hypoestrogenic symptoms: Hot flashes, sweating, palpitations.
Specific risks: Endometrial hyperplasia and carcinoma (due to agonist effects on the uterus), thromboembolism.
Other: Visual disturbances, skin rash, dizziness, gastrointestinal disturbances.
Important: The development of hypercalcemia is an absolute indication for immediate discontinuation of the drug.

Clinical Considerations

Tamoxifen is a substrate for the CYP1A2 isoenzyme, which requires monitoring for drug interactions. The drug is not a pure estrogen, and its efficacy in postmenopausal women is due to the depletion of the estrogen receptor pool (down-regulation) in target tissues.

Mnemonic

Tamoxifen: T-T-T (Tissue-specific, Triphenylethylene, Treatment of breast cancer). Remember: blockade in the breast, support in the bone, risk in the uterus.

Frequently asked questions

Why does tamoxifen increase the risk of endometrial cancer?: In endometrial tissue, tamoxifen exhibits properties of a partial estrogen receptor agonist, which stimulates proliferative processes in the uterus with prolonged use.
What is the advantage of raloxifene over tamoxifen?: Raloxifene is an antagonist in both breast and endometrial tissues, so it does not increase the risk of uterine hyperplasia and cancer.
What happens to estrogen receptors under the action of tamoxifen?: An unproductive receptor-drug complex is formed, followed by the depletion of the receptor pool (down-regulation).

Go deeper

Comparison of the safety profiles of tamoxifen and toremifene.
The role of coreactivators and corepressors in SERM tissue specificity.
Interaction of tamoxifen with the cytochrome P450 system (CYP1A2).
Differences in the mechanisms of action between tamoxifen and fulvestrant (a pure antagonist).
Patient management strategies upon the development of hypercalcemia during therapy.